Cambridge Investment Research Advisors’s Astera Labs ALAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.5M Buy
40,269
+8,606
+27% +$2.28M 0.04% 424
2026
Q1
$3.47M Buy
31,663
+5,936
+23% +$845K 0.01% 1191
2025
Q4
$4.28M Sell
25,727
-3,894
-13% -$651K 0.01% 1009
2025
Q3
$5.8M Buy
29,621
+6,611
+29% +$1.09M 0.02% 829
2025
Q2
$2.08M Buy
23,010
+9,104
+65% +$719K 0.01% 1407
2025
Q1
$830K Buy
13,906
+5,416
+64% +$501K ﹤0.01% 2010
2024
Q4
$1.13M Buy
+8,490
New +$797K ﹤0.01% 1773

Other funds holding ALAB

Cambridge Investment Research Advisors's ALAB Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Astera Labs (ALAB) stake by 27% in Q2 2026, buying an estimated $2.28M and bringing the position to 40,269 shares worth $19.5M. The position accounts for 0.04% of the portfolio, ranked #424.

Cambridge Investment Research Advisors first reported a position in ALAB in Q4 2024 and has held it in 7 quarters since. 988 funds tracked by Wall St. Rank hold ALAB as of Q2 2026.

  • Cambridge Investment Research Advisors held 40,269 shares of Astera Labs worth $19.5M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 8,606 Astera Labs shares in Q2 2026, an estimated $2.28M.
  • Astera Labs made up 0.04% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #424 holding.
  • Cambridge Investment Research Advisors first reported a position in Astera Labs in Q4 2024 and has held it in 7 quarters since.
  • 988 funds tracked by Wall St. Rank held Astera Labs as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.